# Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

> **NCT01414153** · PHASE2 · COMPLETED · sponsor: **Lpath, Inc.** · enrollment: 158 (actual)

## Conditions studied

- Exudative Age-related Macular Degeneration

## Interventions

- **DRUG:** 4.0 mg iSONEP
- **DRUG:** 0.5 mg iSONEP
- **DRUG:** 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- **DRUG:** sham injection

## Key facts

- **NCT ID:** NCT01414153
- **Lead sponsor:** Lpath, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01414153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01414153, "Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01414153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*